Amer M Zeidan on Muck Rack

Amer M Zeidan

New Haven
As seen in: Color Research & Application, Nature, Wiley, Wiley Online Library, PLOS, ScienceDirect, Educational Studies, Taylor & Francis Online, The New England Journal of Medicine, The Lancet and
Cancer doctor. Leukemia fighter. Hala @RealMadrid. Focus on #AMLsm & #MDSsm. Opinions are solely my own. COI bit.ly/2YfwJ9V
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Amer M

Contact Amer M, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

EHA 2026 AML Highlights: What New Combinations Mean for Survival

|
By Amer M Zeidan
| Oncology News Central Verified
This transcript has been lightly edited for clarity. Amer Zeidan, MBBS, MD: Hi everyone. My name is Amer Zeidan. I’m a professor of medicine at Yale University and the chief of the Division of Hematologic Malignancies at Yale Comprehensive Cancer Center. It’s my pleasure to be here with you with Oncology News Central. I am reporting after the European Hematology Association meeting that took place in Stockholm to review some of the most important abstracts in acute myeloid leukemia. Okay.
Open in Who Shared Issue with article?

Beyond the Catalogue: Design and Biological Enrichment as the Next Priorities in Higher-Risk MDS Drug Development

|
By Amer M Zeidan, Petri Bono, Joab Williamson
| Wiley Online Library Verified
, , and , “Beyond the Catalogue: Design and Biological Enrichment as the Next Priorities in Higher-Risk MDS Drug Development,” European Journal of Haematology (2026): 1–2, https://doi.org/10.1111/ejh.70244. No abstract is available for this article. Data Availability Statement No new data were generated for this letter. References 1 and , “Novel Therapies in High-Risk Myelodysplastic Syndromes,” European Journal of Haematology 116, no. 6 (2026): 744–758, https://doi.org/10.1111/ejh.70146.
Open in Who Shared View Duplicates (48) Issue with article?

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia

|
By Gail J. Roboz, Amer M Zeidan
| The New England Journal of Medicine Verified
Are you a member of an institution such as a university or hospital?Learn more about Institutional Access Notes A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by Taiho Oncology. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Open in Who Shared Issue with article?
See all 67 licensed articles (188 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified